Prognostic value of response after three MOPP cycles in Hodgkin's disease--stage III and IV
Autor: | A. Barbot, Mathieu Monconduit, R. Le Fur, H. Tilly, H. Piguet, Jean-François Ménard |
---|---|
Rok vydání: | 1987 |
Předmět: |
medicine.medical_specialty
Vincristine Time Factors Drug Resistance Procarbazine Vinblastine Gastroenterology Bleomycin Prednisone Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Mechlorethamine Stage (cooking) Neoplasm Staging Retrospective Studies Hematology business.industry Hodgkin's Disease Stage III General Medicine Prognosis Hodgkin Disease Surgery Dacarbazine B symptoms Doxorubicin Methotrexate medicine.symptom business medicine.drug |
Zdroj: | Blut. 54(3) |
ISSN: | 0006-5242 |
Popis: | Sixty-eight patients with Hodgkin's disease stage III and IV were evaluated after three out of six MOPP cycles. At that time, 46 (68%) were classified as early responders and 22 as slow responders. The criteria of response were: disappearance of B symptoms, decrease in the size of the largest lymph nodes (by more than 50%) and significant reduction (more than 20%) of mediastinal enlargement. Out of 43 early responders, 38 were in complete remission after six MOPP cycles and only five out of 22 slow responders. Such an early response is only related to the absence of B symptoms at the time of diagnosis (p less than 0.05). The survival curves of early responders and slow responders were significantly different (p less than 0.02). A rapid erythrocyte sedimentation rate (ESR) (greater than 50 mm) was the most frequently abnormal sign found in the group not responding after three MOPP cycles (p less than 0.0001). Such a significant prognostic value of early response is observed for stage III but not for stage IV patients. We conclude that early clinical response after three MOPP cycles is a good prognostic factor which must be kept in mind in the formulation of the therapeutic regimen for Hodgkin's disease stage III and IV. |
Databáze: | OpenAIRE |
Externí odkaz: |